Decera Clinical Education Oncology Podcast

In this episode, Frederick L. Locke, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with lymphomas, with questions including:How does the recent approval of lisocabtagene maraleucel and the expanded indication for axicabtagene ciloleucel add to the treatment landscape for DLBCL? Do you see CAR T-cell therapy ever being used in the first-line setting for DLBCL?How should physicians select patients for CAR T-cell therapy vs ASCT in DLBCL?How should physicians sequence CAR T-cell therapy vs BTK inhibitors in MCL?Presenter:Frederick L. Locke, MDCo-LeaderMoffitt Immuno-Oncology ProgramVice Chair and Associate Member Department of Blood and Marrow Transplant and Cellular ImmunotherapyResearch Director and Medical DirectorImmune Cell Therapy ProgramMoffitt Cancer CenterTampa, FloridaContent based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma.Link to full program: https://bit.ly/3rDeFCV Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, D. Ross Camidge, MD, PhD, and Joel W. Neal, MD, PhD, answer questions on investigational antibody-drug conjugates for advanced NSCLC Presenters:Ross Camidge, MD, PhD Professor of Medicine/Oncology University of Colorado Cancer CenterAurora, ColoradoJoel W. Neal, MD, PhD Associate Professor of MedicineDivision of OncologyDepartment of MedicineStanford UniversityAttending PhysicianStanford Cancer InstitutePalo Alto, CaliforniaContent based on an online IME program supported by educational grants from Daiichi Sankyo, Inc .Link to full program:http://bit.ly/3twpIyl Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Noopur Raje, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy, with questions including:Now that belantamab mafodotin is approved for relapsed/refractory multiple myeloma, what are your thoughts on how BCMA-directed CAR T-cell therapy might be sequenced? Is there reason to think CAR T-cell therapy would still be efficacious following belantamab mafodotin?Could BCMA-directed CAR T-cell therapy replace transplant in the first-line setting for multiple myeloma?What are key considerations surrounding the use of tocilizumab for managing cytokine-release syndrome?What are some of the longer-term toxicities associated with CAR T-cell therapy? When do they emerge and how long do they typically last?Presenter:Noopur Raje, MDProfessor of MedicineHarvard Medical SchoolDirectorCenter for Multiple MyelomaMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma.Link to full program:http://bit.ly/3rDeFCV Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr. Shaji Kumar from the Mayo Clinic and Dr. Sagar Lonial from Emory University discuss highlights of the key data from ASH 2020 on the treatment of patients with multiple myeloma. Topics include:Newly diagnosed multiple myelomaRelapsed/refractory multiple myelomaAnti-BCMA therapy: CAR T-cellsAnti-BCMA therapy: bispecific antibodiesAnti-BCMA therapy: antibody–drug conjugatesNovel targeted agents for relapsed/refractory multiple myelomaPresenters:Shaji K. Kumar, MDMark and Judy Mullins Professor of Hematological MalignanciesChair, Myeloma Amyloidosis Dysproteinemia GroupConsultant, Division of HematologyMayo ClinicRochester, MinnesotaSagar Lonial, MDProfessor and ChairDepartment of Hematology and Medical OncologyChief Medical OfficerWinship Cancer Institute of Emory UniversityAtlanta, GeorgiaLink to the CCO website: http://bit.ly/30EqUn0 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jorge Cortes, MD, and Eunice S. Wang, MD, discuss the clinical implications of 3 key studies in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) presented at the virtual ASH 2020 annual conference. Topics include: The macrophage immune checkpoint inhibitor magrolimab in AMLThe STAMP inhibitor asciminib in CML (the ASCEMBL trial)Optimal dosing for the TKI ponatinib in CMLPresenters:Jorge Cortes, MDDirector, Georgia Cancer CenterEminent Scholar, Georgia Research AcademyAugusta, GeorgiaEunice S. Wang, MDProfessor, OncologyChief, Leukemia ServiceDepartment of MedicineRoswell Park Comprehensive Cancer CenterBuffalo, New YorkContent supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology.Link to full program and Capsule Summary downloadable slidesets:https://bit.ly/3tyQ9nG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jamie E. Chaft, MD, provides her expert perspective on new data from WCLC 2020 in early-stage NSCLC, with topics including:Updated results from ADAURA on HRQoL and DFS outcomes with or without postoperative chemotherapy after adjuvant osimertinibAn analysis of the ongoing ITACA study of personalizing chemotherapy based on biomarkers of drug resistanceFDG PET/CT adaptive radiotherapy in RTOG 1106The TALENT study in Taiwan screening nonsmokers for lung cancerPresenter:Jamie E. Chaft, MDAssociate Attending PhysicianThoracic Oncology ServiceMemorial Sloan Kettering Cancer CenterNew York, New YorkContent supported by educational grants from Amgen; Bristol-Myers Squibb; Ipsen Biopharmaceuticals; Janssen Pharmaceutica NV; Jazz Pharmaceuticals; Regeneron Pharmaceuticals, Inc. & Sanofi Genzyme; and Takeda Oncology.Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:http://bit.ly/2NzE6X6 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, José Ignacio Nolazco, MD, and Alejandro Nolazco, MD, discuss in Spanish the latest immuno-oncology developments in the treatment of urothelial cancer from an Argentinian perspective. Presenters:José Ignacio Nolazco, MD Urology FellowHospital Universitario AustralBuenos Aires, ArgentinaAlejandro Nolazco, MDAssociate ProfessorDepartment of UrologyUniversidad Austral and Universidad Católica ArgentinaBuenos Aires, ArgentinaContent based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.Link to full program, including associated downloadable slidesets and on-demand Webcast:https://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, provide their clinical perspectives on new data from ASH 2020 on nonmalignant hematologic disorders, with topics including:Use of mycophenolate mofetil plus corticosteroids vs standard corticosteroid treatment in patients with ITP from the phase III FLIGHT study Analysis of an ongoing phase I/II trial of rilzabrutinib reporting safety and efficacy in the long-term extension for adult patients with relapsed/refractory ITPNew data from the phase III HOPE-B study of etranacogene dezaparvovec gene therapy, using an AAV5-vector to deliver the Padua variant of the factor IX gene in patients with hemophilia B An update from the phase I/II CLIMB THAL-111/SCD-121 studies reporting safety and efficacy on the first 10 patients receiving CTX001 with at least 3 months of follow-upPrimary analysis from the phase III REACH3 trial evaluating ruxolitinib, an oral JAK1/2 inhibitor, in combination with steroids and calcineurin inhibitors, as a treatment for steroid-refractory or steroid-dependent chronic GVHDTop-line results from the phase II ROCKstar study of belumosudil, a ROCK2 kinase inhibitor, in patients with heavily pretreated chronic GVHDPhase I data from the GRAVITAS-119 study of JAK1 inhibitor itacitinib plus calcineurin inhibitors as prophylaxis treatment for acute GVHDPresenters:Hanny Al-Samkari, MDInstructorDepartment of MedicineHarvard Medical SchoolAttending Hematologist and Clinical InvestigatorDivision of Hematology OncologyMassachusetts General HospitalBoston, MassachusettsSujit Sheth, MDProfessorDepartment of PediatricsWeill Cornell MedicineNew York, New YorkMark A. Schroeder, MDAssociate Professor of MedicineDivision of OncologyDepartment of MedicineWashington University School of Medicine in St LouisSt Louis, MissouriContent supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology. Link to full program, including downloadable slidesets, and on-demand Webcasts:http://bit.ly/3tyQ9nG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, provide medical oncology and hematology perspectives on new data from ASH 2020 in MDS and MPNs, with topics including:3-year OS results with RIC allogeneic transplantation in patients with higher-risk MDS in the BMT CTN 1102 studyA post hoc analysis of phase II data on the addition of pevonedistat to azacitidine in higher-risk MDS patients5-year results of ropeginterferon α-2b in polycythemia vera from the CONTINUATION-PV studyPhase II results of luspatercept for anemia in patients with myelofibrosis who are transfusion dependentAnalysis of clinical benefit in patients with myelofibrosis and OS benefit from imetelstat.Presenters:Amy E. DeZern, MD, MHSAssociate ProfessorOncology and MedicineThe Johns Hopkins University School of MedicineBaltimore, MarylandSrdan Verstovsek, MD, PhDProfessorDivision of Cancer MedicineDepartment of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston, TexasContent supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology.Link to full program and Capsule Summary downloadable slidesets:http://bit.ly/3tyQ9nG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, answer questions from a clinician audience on topics related to hemophilia management including:Maintaining long-term musculoskeletal healthIdentifying patients most likely to benefit from pharmacokinetics-guided prophylaxisManaging combination therapies in older patients with comorbiditiesYoungest age at which patients can be considered for emicizumabDevelopment of resistance to emicizumabSwitching recombinant factor therapiesUsing bypassing agents with emicizumab for breakthrough bleeds in patients with inhibitorsPotential clinical role of extending FVIII half-life with BIVV001Considerations when dosing emicizumab monthlyPresenters:Michael Callaghan, MDAssociate ProfessorDepartment of HematologyWayne State UniversityHematologistDivision of Hematology/OncologyChildren’s Hospital of MichiganDetroit, MichiganMiguel A. Escobar, MDProfessor of Medicine and PediatricsDepartment of HematologyUniversity of Texas Health Science CenterMcGovern Medical SchoolDirectorGulf States Hemophilia and Thrombophilia CenterHouston, TexasRebecca Kruse-Jarres, MD, MPHProfessorDepartment of MedicineUniversity of WashingtonExecutive/Medical DirectorWashington Institute for CoagulationSeattle, WashingtonContent supported by educational grants from Genentech, a member of the Roche Group; Sanofi Genzyme Corporation; and Takeda Pharmaceutical Company Ltd.Link to full program, including downloadable slidesets, expert commentaries, and on-demand Webcast: http://bit.ly/2MW5uhi Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Guiseppe Procopio, MD, and Cora N. Sternberg, MD, FACP, discuss in Italian the latest immuno-oncology developments in the treatment of urothelial cancer. Presenters:Guiseppe Procopio, MD Head of the Medical Oncology Genitourinary, Istituto Nazionale TumoriMedical OncologyFondazione IRCCS Istituto Nazionale dei TumoriMilan, ItalyCora N. Sternberg, MD, FACPProfessor of MedicineDepartment of Hematology/OncologyWeill Cornell MedicineNew York, New York, USAContent based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.Link to full program, including associated downloadable slidesets and on-demand Webcast: http://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Petros Grivas, MD, PhD, and Jonathan E. Rosenberg, MD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United States. Topics include:Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapyResults from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapyWhen to consider first-line treatment with immune checkpoint inhibitor monotherapyUtility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapyMonitoring for and managing immune-related adverse events during the COVID-19 pandemic Presenters:Petros Grivas, MD, PhDAssociate ProfessorClinical Director, Genitourinary Cancers ProgramDivision of Medical OncologyDepartment of MedicineUniversity of WashingtonSeattle Cancer Care AllianceSeattle, Washington, USAJonathan E. Rosenberg MDAttending PhysicianChief, Genitourinary Oncology ServiceDivision of Solid Tumor OncologyDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New York, USAContent based on an online IME program supported by educational grants from Pfizer and EMD Serono, Inc.Link to full program, including associated downloadable slidesets and on-demand Webcast:http://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Link to CME: Claim CreditIn this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations in the contemporary use of immune checkpoint inhibitors for treating patients with advanced hepatocellular carcinoma, with topics including:Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumabUse of nivolumab ± ipilimumab and pembrolizumabEmerging immunotherapy combinations currently being investigated in clinical trialsManagement of key adverse events with immune checkpoint inhibitorsPresenters:Amit G. Singal, MD, MSChief of HepatologyMedical Director, Liver Tumor ProgramProfessor, Department of Internal MedicineUT Southwestern Medical CenterDallas, TexasLipika Goyal, MDLead of the Liver Cancer Research ProgramAssistant Professor of MedicineHarvard Medical SchoolMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.Link to full program:http://bit.ly/39V6s72 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Félix Guerrero Ramos, MD, PhD, FEBU, and Óscar Rodríguez-Faba, MD, discuss in Spanish the latest immuno-oncology developments in the treatment of urothelial cancer. Presenters:Félix Guerrero Ramos, MD, PhD, FEBU Teaching CollaboratorDepartment of SurgeryMedicine SchoolUniversidad Complutense de MadridAttending UrologistDepartment of UrologyUroOncology UnitMadrid, Spain Óscar Rodríguez-Faba, MD UrologistUro-OncologyFundació PuigvertBarcelona, Catalonia, SpainContent based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.Link to full program, including associated downloadable slidesets and on-demand Webcast:http://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Nathan Pennell, MD, PhD, and Laura J. Tafe, MD, provide medical oncology and pathology perspectives, respectively, when answering questions from a clinician audience on topics including:Next steps in patient care after identifying a biomarker: selecting treatment, getting insurance approval, arranging for financial assistancePerforming biomarker testing on cytology vs surgical or anatomic pathology specimensFactors affecting turnaround time when testing liquid biopsy vs tissue specimensChoice of a targeted agent vs chemotherapy plus immunotherapy for first-line treatment of patients with RET fusions, BRAF mutations, or MET exon 14 skippingConcordance between IHC and FISH or NGS for ALK rearrangementsUse of fluid cytology specimens when testing for fusions in RET or NTRK and MET amplificationCost considerations with performing multiple single-gene assays vs upfront NGSTesting for driver mutations in early-stage NSCLCDeveloping institutional workflows to enable pathologists to order reflex molecular testing panelsPresenters:Nathan Pennell, MD, PhDProfessorDirector, Cleveland Clinic Lung Cancer Medical Oncology ProgramDepartment of Hematology and Medical OncologyCleveland Clinic Taussig Cancer InstituteCleveland, OhioLaura J. Tafe, MDAssociate Professor of Pathology and Laboratory MedicineDartmouth-Hitchcock Medical CenterLebanon, New HampshireThe Geisel School of Medicine at DartmouthHanover, New HampshireContent supported by an educational grant from Lilly.Link to full program, including an associated Podcast Pearls PDF, downloadable slidesets, and on-demand Webcasts:http://bit.ly/3a3e1Xs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode,William G. Wierda, MD, PhD, Jeremy S. Abramson, MD, MMSc, and Brian Hill, MD, PhD, answer questions focused on personalizing therapy for patients with CLL considering patient characteristics and currently available clinical evidence.Presenters:William G. Wierda, MD, PhD, Program DirectorProfessor of MedicineChief, Section of CLLDepartment of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston, TexasJeremy S. Abramson, MD, MMScAssociate ProfessorDepartment of MedicineHarvard Medical SchoolDirector, Center for LymphomaMassachusetts General HospitalBoston, MassachusettsBrian Hill, MD, PhDDirector, Lymphoid Malignancies ProgramTaussig Cancer InstituteCleveland ClinicCleveland, OhioContent based on an online CME program supported by educational grants from AstraZeneca; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.Link to full program, including associated downloadable slidesets:http://bit.ly/3mLjeIb Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Helena A. Yu, MD, and Maria E. Arcila, MD, provide medical oncology and pathology perspectives, respectively, on new data from ESMO 2020 informing precision medicine in NSCLC, with topics including:Updated efficacy data from the phase III ADAURA study of adjuvant osimertinib for resected EGFR-mutated NSCLC with a focus on CNS disease recurrenceBiomarker testing in early-stage lung cancer New data for sotorasib, a small molecule inhibitor of KRAS G12C, in heavily pretreated NSCLCInterim results from the phase I portion of the CHRYSALIS trial evaluating amivantamab, a bispecific antibody that targets EGFR and MET, in combination with lazertinib, a third-generation EGFR TKI, for the treatment of EGFR-mutated NSCLCPhase I data on the HER3-directed antibody–drug conjugate patritumab deruxtecan for NSCLC with progression on an EGFR TKIPresenters:Helena A. Yu, MDAssistant AttendingDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkMaria E. Arcila, MDPathologistDirector, Diagnostic Molecular Pathology LaboratoryMemorial Sloan Kettering Cancer CenterNew York, New YorkContent supported by an educational grant from Lilly.Link to full program, including an associated Podcast Pearls PDF, downloadable slidesets, and on-demand Webcasts:http://bit.ly/3a3e1Xs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Link to CME: Claim CreditIn this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, answer clinician questions on current best practices and emerging applications with immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma, with topics including:Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumabUse of immune checkpoint inhibitor therapy in patients with Child-Pugh B liver functionUse of biomarkers to inform treatment for patients with advanced HCCPresenters:Amit G. Singal, MD, MSChief of HepatologyMedical Director, Liver Tumor ProgramProfessor, Department of Internal MedicineUT Southwestern Medical CenterDallas, TexasLipika Goyal, MDLead of the Liver Cancer Research ProgramAssistant Professor of MedicineHarvard Medical SchoolMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.Link to full program:https://bit.ly/39V6s72 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Thomas Powles, MBBS, MRCP, MD, and Michiel van der Heijden, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United Kingdom and the Netherlands. Topics include:Data from registrational trials in the European Union for pembrolizumab and atezolizumab in the first-line/second-line settingsUtility of PD-L1 and tumor mutational burden as biomarkers for immune checkpoint inhibitor–based therapyResults from the JAVELIN trial on avelumab maintenance after chemotherapyWhen to consider first-line treatment with immune checkpoint inhibitor–based therapy vs chemotherapyPresenters:Thomas Powles, MBBS, MRCP, MDDeputy Centre LeadCentre for Experimental Cancer MedicineBarts Cancer InstituteQueen Mary University of LondonProfessor of Urology CancerDirector of Barts Cancer CentreDepartment of CancerSt Bartholomew's Hospital (Barts Health NHS Trust)London, United KingdomMichiel van der Heijden, MD, PhDMedical Oncologist and Research Group LeaderDepartment of Medical Oncology and Molecular CarcinogenesisStichting Het Nederlands Kanker Instituut – Antoni van Leeuwenhoek ZiekenhuisMedical Oncologist Antoni van Leeuwenhoek Ziekenhuis/Netherlands Cancer InstituteAmsterdam, the NetherlandsContent based on an online IME program supported by educational grants from Pfizer and EMD Serono, Inc.Link to full program, including associated downloadable slidesets and on-demand Webcast:https://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Alain Ravaud, MD, PhD, and Marine Gross-Goupil, MD, PhD, discuss in French the latest immuno-oncology developments in the treatment of urothelial cancer. Presenters:Alain Ravaud, MD, PhD Professor of Medical OncologyHead of Department of Medical OncologyBordeaux University HospitalBordeaux, FranceMarine Gross-Goupil, MD, PhD Medical OncologistSaint-André HospitalBordeaux University HospitalBordeaux, FranceContent based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.Link to full program:https://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of molecular testing and classification to guide the use of immunotherapy for the treatment of patients with endometrial cancer. Presenters:Ana Oaknin, MD, PhDHead of Gynecologic Tumors UnitMedical Oncology DepartmentVall d´Hebron University HospitalBarcelona, Spain Mansoor Raza Mirza, MDChief OncologistDepartment of Oncology,Rigshopitalet – Copenhagen University HospitalCopenhagen, DenmarkContent based on an online CME program supported by an educational grant from GlaxoSmithKline.Link to full program:https://bit.ly/3kpJeaG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of immunotherapy for the treatment of patients with endometrial cancer.Presenters:Ana Oaknin, MD, PhDHead of Gynecologic Tumors UnitMedical Oncology DepartmentVall d´Hebron University HospitalBarcelona, Spain Mansoor Raza Mirza, MDChief OncologistDepartment of Oncology,Rigshopitalet – Copenhagen University HospitalCopenhagen, Denmark Content based on an online CME program supported by an educational grant from GlaxoSmithKline.Link to full program:https://bit.ly/3kpJeaG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, David Marks, MD, PhD, and Stéphane de Botton, MD, answer questions from clinicians on management pearls for patients with acute leukemias. Topics include:MRD in the management of ALLTherapy choice for older patients with AMLOptimal use of inotuzumab ozogamicin and blinatumomab for ALLUse of CAR T-cell therapy for acute leukemiasContent based on an online CME program supported by an educational grant from Pfizer Inc.Link to full program:https://bit.ly/3jiCBaD Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Isabelle Ray Coquard, MD, PhD and Bradley J. Monk, MD, FACS, FACOG, discuss current first-line maintenance therapy options for patients with advanced ovarian cancer. Presenters:Prof Isabelle Ray CoquardProfessor of Department of Medical OncologyClinical Science Institute of the Léon Bérard CenterLyon, FranceBradley J. Monk MD, FACS, FACOGProfessorDivision of Gynecologic OncologyArizona Oncology (US Oncology Network)University of Arizona College of Medicine--PhoenixCreighton University School of Medicine at St Joseph's HospitalPhoenix, ArizonaContent based on an online CME program supported by an educational grant from GlaxoSmithKline.Link to full program:https://bit.ly/2Scnp2N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to Prof Nicoletta Colombo and Bradley J. Monk, MD, FACS, FACOG, discuss current best practices for biomarker testing for your patients with advanced ovarian cancer.In this episode, Prof Nicoletta Colombo and Bradley J. Monk, MD, FACS, FACOG, discuss current best practices for biomarker testing in the management of patients with advanced ovarian cancer. Topics include:Subtypes of ovarian cancerBRCA mutation testing Homologous recombination deficiency testing Presenters:Professor Nicoletta ColomboProfessor of Obstetrics and GynecologyUniversity of Milan-BicoccaEuropean Institute of OncologyMilan, ItalyBradley J. Monk MD, FACS, FACOGProfessorDivision of Gynecologic OncologyArizona Oncology (US Oncology Network)University of Arizona College of Medicine--PhoenixCreighton University School of Medicine at St Joseph's HospitalPhoenix, ArizonaContent based on an online CME program supported by an educational grant from GlaxoSmithKline.Link to full program:https://bit.ly/2Scnp2N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss clinical considerations for patients with HER2-positive MBC, with topics including:Local therapy in the context of MBCChoice of therapy after progression on available standards of careChoice of trastuzumab deruxtecan and tucatinib based on patient presentationManaging patients with CNS metastasesManaging interstitial lung diseasePresenters:Thomas Bachelot, MD, PhDChair, Unicancer Breast Group - UCBGBreast Cancer UnitMedical Oncology Centre Léon BérardLyon, FranceAdam M. Brufsky, MD, PhDProfessor of Medicine Hematology/Oncology University of Pittsburgh School of MedicineAssociate Chief, Hematology-OncologyUniversity of Pittsburgh Cancer InstitutePittsburgh, PennsylvaniaCristina Saura, MD, PhDMedicine and Surgery/Medical OncologyUniversidad Universitat Autònoma Barcelona and Vall d’Hebron Institute of Oncology (VHIO)Head, Breast Cancer ProgramMedical OncologyVall d’Hebron University HospitalBarcelona, SpainContent based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc. Link to full program, including associated downloadable slidesets:https://bit.ly/32A1HMb Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, an expert medical oncology panel led by Elizabeth R. Plimack, MD, MS, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses clinical pearls for the management of patients with metastatic renal cell carcinoma (RCC). Topics include:Treating beyond progression with immunotherapyManagement of patients with less common histologic subtypes of RCCPotential biomarkers for RCCAdverse event managementPresenters:Elizabeth R. Plimack, MD, MSChief, Division of Genitourinary Medical Oncology Director, Genitourinary Clinical Research Professor, Department of Hematology/Oncology Fox Chase Cancer Center Temple Health Philadelphia, PennsylvaniaBrian A. Costello, MDAssociate Professor of Oncology and UrologyDivision of Medical OncologyMayo ClinicRochester, MinnesotaMartin H. Voss, MDClinical Director, Genitourinary Medical Oncology ServiceMemorial Sloan Kettering Cancer CenterAssistant Professor Weill Cornell Medical CollegeNew York, New YorkContent based on an online CME program supported by educational grants from Eisai, Exelixis, and Pfizer and EMD Serono.Link to full program:https://bit.ly/32IS9gx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer questions focused on the optimizing BTK inhibitor therapy for previously untreated patients with CLL considering presentation characteristics and drug pharmacology.Presenters:Jeff P. Sharman, MD, Program DirectorMedical DirectorHematology ResearchUS Oncology ResearchEugene, OregonDanielle M. Brander, MDAssistant Professor of MedicineDivision of Hematologic Malignancies & Cellular TherapyDepartment of MedicineDuke UniversityAttending Physician, Hematologic MalignanciesDuke University Health SystemDurham, North CarolinaNicole Lamanna, MDAssociate AttendingLeukemia ServiceDirector of CLL ProgramHematologic Malignancies SectionDepartment of MedicineNew York-Presbyterian/Columbia University Medical Center New York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program, including associated downloadable slidesets:https://bit.ly/3hATX0L Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including:• The impact of COVID-19 on CLL treatment decisions• The use of anti-CD20 antibodies in combination with BTK inhibitors• Considerations when recommending BTK inhibitors• MRD testing in patients with CLL• The potential impact of targeted therapies on when to start treatmentPresenters:Jeff P. Sharman, MD, Program DirectorMedical DirectorHematology ResearchUS Oncology ResearchEugene, OregonDanielle M. Brander, MDAssistant Professor of MedicineDivision of Hematologic Malignancies & Cellular TherapyDepartment of MedicineDuke UniversityAttending Physician, Hematologic MalignanciesDuke University Health SystemDurham, North CarolinaNicole Lamanna, MDAssociate AttendingLeukemia ServiceDirector of CLL ProgramHematologic Malignancies SectionDepartment of MedicineNew York-Presbyterian/Columbia University Medical Center New York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program, including associated downloadable slidesets: https://bit.ly/3hATX0L Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, with topics including:Optimal testing for RET fusionsDNA NGS vs RNA NGSMolecular testing workflowsUsing new selective RET inhibitors to treat patients with RET fusion–positive NSCLCCommon toxicities with new selective RET inhibitorsInterdisciplinary communication between medical oncologists and pathologistsPresenters:Dara L. Aisner, MD, PhDAssociate ProfessorDepartment of PathologyDirector, Molecular PathologyUniversity of ColoradoAurora, ColoradoJoshua Bauml, MDAssistant Professor of MedicineDivision of Hematology/OncologyPerelman School of Medicine at the University of PennsylvaniaPhiladelphia, PennsylvaniaLink to full program, including associated downloadable slidesets:https://bit.ly/2Fsq9Wv Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including:Rechallenging patients with venetoclax and BTK inhibitors Mechanism by which BTK inhibitors may reduce infusion reactionsRisk of secondary malignancies with BTK inhibitionDifferent cytogenetic findings and adverse event riskPresenters:Jeff P. Sharman, MD, Program DirectorMedical DirectorHematology ResearchUS Oncology ResearchEugene, OregonDanielle M. Brander, MDAssistant Professor of MedicineDivision of Hematologic Malignancies & Cellular TherapyDepartment of MedicineDuke UniversityAttending Physician, Hematologic MalignanciesDuke University Health SystemDurham, North CarolinaNicole Lamanna, MDAssociate AttendingLeukemia ServiceDirector of CLL ProgramHematologic Malignancies SectionDepartment of MedicineNew York-Presbyterian/Columbia University Medical Center New York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program, including associated downloadable slidesets:https://bit.ly/3hATX0L Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Michael R. Bishop, MD; Daniel J. DeAngelo, MD, PhD; and Noopur Raje, MD, answer clinician questions on current best practices and emerging applications with CAR T-cell therapy, with topics including:Optimal use of approved CAR T-cell therapies for lymphoma and ALLInvestigational CAR T-cell therapies for multiple myelomaManaging CAR T-cell therapy–related toxicitiesPresenters:Michael R. Bishop, MDProfessor of MedicineSection of Hematology/OncologyDirector, Cellular Therapy ProgramUniversity of ChicagoChicago, IllinoisDaniel J. DeAngelo, MD, PhDProfessor of MedicineDepartment of MedicineHarvard Medical SchoolChief, Division of LeukemiaDepartment of Medical OncologyDivision of Hematologic MalignanciesDana‐Farber Cancer InstituteBoston, MassachusettsNoopur Raje, MDProfessor of MedicineHarvard Medical SchoolDirectorCenter for Multiple MyelomaMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by educational grants from Celgene Corporation and Legend Biotech USA Inc.Link to full program:https://bit.ly/3iyt5zQ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, an expert medical oncology panel, led by Elizabeth R. Plimack, MD, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses current best practices for the second-line treatment and beyond of patients with metastatic renal cell carcinoma (RCC). Topics include:• Treatment sequencing with IO and TKI therapies• Optimizing dose for patients with preexisting toxicities• Considerations for local control of metastatic sites • Ongoing clinical trials Presenters:Elizabeth R. Plimack, MD, MSChief, Division of Genitourinary Medical Oncology Director, Genitourinary Clinical Research Professor, Department of Hematology/Oncology Fox Chase Cancer Center Temple Health Philadelphia, PennsylvaniaBrian A. Costello, MDAssociate Professor of Oncology and UrologyDivision of Medical OncologyMayo ClinicRochester, MinnesotaMartin H. Voss, MDClinical Director, Genitourinary Medical Oncology ServiceMemorial Sloan Kettering Cancer CenterAssistant Professor Weill Cornell Medical CollegeNew York, New YorkContent based on an online CME program supported by an educational grant from Eisai, Exelixis, and Pfizer and EMD Serono.Link to full program:https://bit.ly/32IS9gx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jesús F. San-Miguel, MD, PhD; Paula Rodriguez-Otero, MD, PhD; and Prof. Dr. med. Katja Weisel answer questions focused on current and emerging therapies for early and late relapsed, refractory multiple myeloma, with topics including:• Responses across different subgroups treated with idecabtagene vicleucel in the KarMMa trial • Selecting therapy for a patient with lenalidomide-refractory disease at first relapse• How CAR T-cell therapy, melflufen, and selinexor will fit into existing and future treatment algorithms• Key findings from the DREAMM2 trial on belantamab mafodotin• Monitoring and management strategies for ocular toxicity with belantamab mafodotinPresenters:Jesús F. San-Miguel, MD, PhDDirector of Clinical and Translational MedicineUniversidad de NavarraPamplona, SpainPaula Rodriguez-Otero, MD, PhDAssociate ProfessorConsultant in HematologyDepartment of Hematology, Clínica Universidad de NavarraUniversity of NavarraPamplona, SpainProf. Dr. med. Katja Weisel Deputy DirectorII. Medical Clinic and PolyclinicDepartment of Oncology and HematologyDepartment of Pneumology and Bone Marrow TransplantationUniversity Medical Center Hamburg-EppendorfHamburg, GermanyContent based on an online CME program supported by an educational grant from GlaxoSmithKline.Link to full program, including associated downloadable slidesets: https://bit.ly/2QRqYuC Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Natalie S. Callander, MD, and Shaji Kumar, MD, answer audience questions from a live CCO Webinar on relapsed/refractory myeloma regarding challenges in treating patients in this setting, including optimizing treatment choices and sequencing of treatments, MRD testing in myeloma, promising BCMA-targeted agents, the promise and value of CAR T-cell therapy in myeloma, and more.Presenters:Natalie S. Callander, MDProfessor of Medicine Director, Myeloma Clinical Program University of Wisconsin Carbone Cancer CenterMadison, WisconsinShaji Kumar, MDDepartment of HematologyMayo ClinicRochester, MinnesotaContent based on an online CME program supported by educational grants from GlaxoSmithKline LLC and Sanofi Genzyme.Link to full program, including associated downloadable slidesets: https://bit.ly/3gT324y Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss current best practices for the first-line treatment of patients with metastatic renal cell carcinoma (RCC). Topics include:Choice of first-line therapyCombinations of targeted agents and immunotherapyCombinations of immune checkpoint inhibitorsActive surveillance and monitoringCytoreductive nephrectomyPresenters:Elizabeth R. Plimack, MD, MSChief, Division of Genitourinary Medical Oncology Director, Genitourinary Clinical Research Professor, Department of Hematology/Oncology Fox Chase Cancer Center Temple Health Philadelphia, PennsylvaniaBrian A. Costello, MDAssociate Professor of Oncology and UrologyDivision of Medical OncologyMayo ClinicRochester, MinnesotaMartin H. Voss, MDClinical Director, Genitourinary Medical Oncology ServiceMemorial Sloan Kettering Cancer CenterAssistant Professor Weill Cornell Medical CollegeNew York, New YorkContent based on an online CME program supported by educational grants from Eisai, Exelixis, Pfizer and EMD Serono, and Merck Sharp & Dohme Corp.Link to full program: https://bit.ly/32IS9gx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in Waldenström macroglobulinemia, mantle cell lymphoma, Hodgkin lymphoma, and DLBCL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies include:ASPEN: Zanubrutinib vs ibrutinib in WMOASIS: Ibrutinib, venetoclax, and obinutuzumab in MCLGHSG HD17: PET-guided therapy in HLKEYNOTE-024: Pembrolizumab vs brentuximab in HLALEXANDER: AUTO3 in DLBCLPresenters:Jennifer R. Brown, MD, PhDAssociate Professor of MedicineDepartment of Hematologic MalignanciesDana-Farber Cancer InstituteHarvard Medical SchoolDirector, CLL CenterDepartment of Medical OncologyDana-Farber Cancer InstituteBoston, MassachusettsJohn Allan, MDAssistant Professor of MedicineDivision of Hematology and Medical OncologyWeill Cornell MedicineNew York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program: https://bit.ly/3aSfekM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on MET exon 14 testing and selecting MET-targeted therapies for patients with advanced NSCLC with topics including:Incorporating MET exon 14 testing into standard of careComparison of RNA-based and DNA-based NGS platformsAvailability of RNA-based NGS testing around the worldUsing FISH to quantify MET copy gain/amplificationRegulatory and clinical differences between new, selective MET inhibitorsSafety profiles of type I vs type II MET inhibitorsCounseling patients on management of peripheral edema, a class effect with MET inhibitor therapyInsights on combining MET inhibition with immune checkpoint inhibition therapy or chemotherapySelecting second-line therapy for a patient with MET exon 14–altered NSCLC progressing on tepotinib or capmatinibPresenters:Luis Paz-Ares, MD, PhDMedical OncologyUniversity Hospital Doce de OctubreMadrid, SpainD. Ross Camidge, MD, PhDProfessor of Medicine/OncologyUniversity of Colorado Cancer CenterAurora, ColoradoKaren L. Reckamp, MD, MSProfessor of MedicineDirector, Division of Medical OncologyDepartment of MedicineCedars SinaiLos Angeles, CaliforniaContent based on an online CME program supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.Link to full program, including associated downloadable slidesets:https://bit.ly/2ExadCf Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on biomarking testing and the use of immunotherapy in METex14 mutation–positive NSCLC with topics including:Whether testing for MET exon 14 status should be standard of careParallel vs sequential testing by DNA-based vs RNA-based NGSCo-occurring driver mutations in patients with METex14 mutation–positive NSCLCOptimal use of immune checkpoint inhibitor–based therapy in the setting of METex14-positive disease, including sequencing with MET inhibitor–based therapyEMA regulatory considerations for the new, selective MET inhibitors tepotinib and capmatinibPresenters:Luis Paz-Ares, MD, PhD Medical OncologyUniversity Hospital Doce de OctubreMadrid, SpainD. Ross Camidge, MD, PhDProfessor of Medicine/OncologyUniversity of Colorado Cancer CenterAurora, ColoradoKaren L. Reckamp, MD, MSProfessor of MedicineDirector, Division of Medical OncologyDepartment of MedicineCedars SinaiLos Angeles, CaliforniaLink to full program, including associated downloadable slidesets: https://bit.ly/2ExadCf Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Anna F. Farago, MD, PhD, and Taofeek K. Owonikoko, MD, PhD, answer questions focused on the topic of current and evolving use of immunotherapy in patients with advanced small-cell lung cancer with topics including:Selecting between atezolizumab and durvalumab in the frontline settingIntegration of lurbinectedin, a novel anticancer drug that was recently approved for the treatment of relapsed SCLC after platinum-based chemotherapy, into patient careWhich patients should receive salvage therapy with an immune checkpoint inhibitor in the third-line settingManagement of brain metastases in patients with advanced SCLCPresenters:Anna F. Farago, MD, PhDAssistant Professor of MedicineDepartment of MedicineHarvard Medical SchoolAssistant in MedicineDivision of Hematology/OncologyDepartment of MedicineMassachusetts General HospitalBoston, Massachusetts Taofeek K. Owonikoko, MD, PhDProfessorDepartment of Hematology and Medical OncologyCo-Leader, Thoracic OncologyEmory UniversityAtlanta, GeorgiaContent based on an online CME program supported by educational grants from Genentech, a member of the Roche Group, and Merck Sharp & Dohme Corp. Link to full program, including associated downloadable slidesets: https://bit.ly/3aTzthZ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in CLL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies and topics include:ASCEND: acalabrutinib vs idelalisib plus rituximab or BRACE-CL-001: acalabrutinib long-term efficacyCLL14: Venetoclax plus obinutuzumabCLARITY: Ibrutinib plus venetoclaxMeasurable residual disease (MRD)Complex karyotypesZanubrutinib plus obinutuzumab and venetoclaxPresenters:Jennifer R. Brown, MD, PhDAssociate Professor of MedicineDepartment of Hematologic MalignanciesDana-Farber Cancer InstituteHarvard Medical SchoolDirector, CLL CenterDepartment of Medical OncologyDana-Farber Cancer InstituteBoston, MassachusettsJohn Allan, MDAssistant Professor of MedicineDivision of Hematology and Medical OncologyWeill Cornell MedicineNew York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program: https://bit.ly/3aSfekM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Naval G. Daver, MD, discusses promising investigational agents and treatment combinations in clinical trials for patients with newly diagnosed and relapsed/refractory AML, including:FLT3 inhibitors crenolanib and quizartinibAnti-CD47 antibody magrolimabIMGN632, a CD123 antibody–drug conjugateAnti-CD70 antibody cusatuzumabAPR-246, targeting the TP53 mutationContent is part of an online CME program supported by an educational grant from Daiichi-Sankyo.Link to full program, including a ClinicalThought commentary: https://bit.ly/2Y2uCG2 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, George D. Demetri, MD; Alexander Drilon, MD; and Pashtoon Kasi, MD, answer questions about NTRK fusion testing and TRK inhibitor therapy for patients with advanced solid tumors, with topics including:Best practices in testing for NTRK fusions in solid tumorsOptimal use of approved TRK inhibitorsKey adverse events with TRK inhibitors and management strategiesEmerging next-generation TRK inhibitors and their potential use in managing resistance to first-generation agentsPresenters:George D. Demetri, MDProfessor of MedicineHarvard Medical SchoolHarvard UniversityCo-Director, Ludwig Center at HarvardSenior Vice President for Experimental Therapeutics Director, Sarcoma CenterDana-Farber Cancer InstituteBoston, MassachusettsAlexander Drilon, MDChief, Early Drug DevelopmentAttending, Thoracic OncologyMemorial Sloan Kettering Cancer CenterNew York, New YorkPashtoon Kasi, MDAssistant ProfessorCollege of Medicine and OncologyHolden Comprehensive Cancer CenterUniversity of IowaIowa City, IowaContent based on an online CME program supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc. and Genentech.Link to full program: https://bit.ly/2PN0BWh Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Prof. Dr. med Tim Henrik Brümmendorf; Jorge Cortes, MD; and Carlo Gambacorti-Passerini, MD, answer questions focused on the optimal selection and management of tyrosine kinase inhibitor (TKI) therapy in patients with CML, with topics including:Frontline Management of Chronic-Phase CMLSelection of TKI Based on Goal of Treatment-Free RemissionChanging TKIs due to Intolerance: Second-line Therapy and Toxicity ManagementChanging TKIs due to CML Progression: Second-line Therapy and Future OptionsPresenters:Prof. Dr. med Tim Henrik BrümmendorfHeadDepartment of Hematology, Oncology, Hematostaseology, and Stem Cell TransplantationUniversity Hospital Aachen, RWTH AachenAachen, GermanyJorge Cortes, MDDirector, Georgia Cancer CenterEminent Scholar, Georgia Research AcademyAugusta, Georgia, USACarlo Gambacorti-Passerini, MDProfessor, HematologyUniversity Milano BicoccaDirector, HematologySan Gerardo HospitalMonza, Italy Content based on an online CME program supported by an educational grant from Pfizer Inc.Link to full program, including associated downloadable slidesets: https://bit.ly/30P8Uaf Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, an expert medical oncology panel led by John L. Marshall, MD, with Jamie E. Chaft, MD, and Scot Niglio, MD, provides a brief overview on the revolutionary changes brought by immuno-oncology to the management of gastrointestinal, thoracic, and genitourinary cancers. Then, the panel answers clinician questions on important topics such as:Selecting immuno-oncology vs targeted therapy in MSI-high cancers with co-occurring alterations (eg, BRCA, HER2, BRAF, NTRK)Switching to a new immuno-oncology strategy at progression on first-line immune checkpoint inhibitionNeoadjuvant treatment with immune checkpoint inhibitorsFinancial considerations when selecting chemotherapy vs immuno-oncologyPresenters:John L. Marshall, MDChief, Division of Hematology/OncologyDepartment of MedicineGeorgetown University HospitalWashington, DCJamie E. Chaft, MDAssociate Attending PhysicianThoracic Oncology ServiceMemorial Sloan Kettering Cancer CenterNew York, New YorkScot Niglio, MDMedical OncologistBethesda, MarylandContent based on an online CME program supported by an educational grant from Merck Sharp & Dohme Corp.Link to full program:https://bit.ly/31vQtqb Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on biomarker testing and selecting targeted therapy for patients with advanced non-small-cell lung cancer with topics including:How to approach discordant results with liquid vs tissue biopsiesRepeating NGS testing at progressionSelecting urgent treatment when molecular results are not yet availablePoint mutations in NTRK fusion–positive diseaseSelecting second-line therapy for EGFR-positive disease with high PD-L1 expression after first-line TKISelecting first-line and second-line therapy for ROS1-positive diseaseStandard of care for MET-altered diseaseSelecting second-line therapy for RET fusion–positive disease after first-line TKIPresenters:Edward S. Kim, MD, FACPChair, Solid Tumor Oncology and Investigational TherapeuticsDonald S. Kim Distinguished Chair for Cancer ResearchLevine Cancer InstituteAtrium HealthCharlotte, North CarolinaLeora Horn, MD, MSc, FRCPCIngram Associate Professor of Cancer ResearchDirector, Thoracic Oncology Research ProgramAssistant Vice Chairman for Faculty DevelopmentVanderbilt Ingram Cancer CenterNashville, TennesseeContent based on an online CME program supported by an educational grant from Lilly.Link to full program, including associated downloadable slidesets: https://bit.ly/3a3e1Xs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on current and evolving biomarkers for immune checkpoint inhibitor–based therapies in advanced non-small-cell lung cancer with topics including:Selecting therapy for advanced NSCLC without actionable mutations and with different levels of PD-L1 expressionChoosing therapy for advanced NSCLC with an actionable mutation on NGS and high PD-L1 expressionLeveraging key data from CheckMate 9LA to identify patients who may benefit from chemotherapy plus nivolumab/ipilimumabSTK11/KEAP1 as potential predictors for a lack of response to immune checkpoint inhibitor–based therapyTreatment for NSCLC after progression on chemotherapy plus an immune checkpoint inhibitorRechallenging after stopping immune checkpoint inhibitor due to immune-related adverse eventsPresenters:Edward S. Kim, MD, FACPChair, Solid Tumor Oncology and Investigational TherapeuticsDonald S. Kim Distinguished Chair for Cancer ResearchLevine Cancer InstituteAtrium HealthCharlotte, North CarolinaLeora Horn, MD, MSc, FRCPCIngram Associate Professor of Cancer ResearchDirector, Thoracic Oncology Research ProgramAssistant Vice Chairman for Faculty DevelopmentVanderbilt Ingram Cancer CenterNashville, TennesseeContent based on an online CME program supported by an educational grant from Lilly.Link to full program, including associated downloadable slidesets: https://bit.ly/3a3e1Xs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.